NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

And Gilead payed $11.9 billion for a drug that had sales of $240 million in 2018.

At a cost of $373,000 per patient that means Gilead paid $11.9 billion for a drug that treated 659 people in 2018.

When put like that... it really doesn't sound like a very smart purchase.
In fact, it sounds rather stupid of Gilead, at least to me.